Company profile
Alnylam Pharmaceuticals, Inc.
NASDAQ: ALNY · Healthcare · Biotechnology
#74 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
79B+FH 83DQ 72GM 78SS 89
v0.1 · 65/100 weight · provisional
↑ market scale, return on equity · ↓ balance-sheet leverage, disclosure history
Methodology →Revenue TTM
$4.3B
Rev growth YoY (TTM)
+82.6%
Net income (FY)
$313.7M
Employees
2,500
as of 2026-08-04
Market cap
$29.5B
as of 2026-08-04
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.7B$3.7B2025
Net income$313.7M$313.7M2025
Operating income$501.6M$501.6M2025
Total assets$5.0B$5.0B2025
Liabilities$4.2B$4.2B2025
Equity$789.2M$789.2M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY23
FY23
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
GIVLAARI64%
ONPATTRO36%
By geography
UNITED STATES75%
Europe18%
Non-US Or Europe8%
The read
What is Alnylam Pharmaceuticals, Inc.’s revenue?
Alnylam Pharmaceuticals, Inc. booked $3.7B in FY2025 revenue, growing 65% year over year — faster than most Healthcare companies we track, at a 8.4% net margin.
Peers · Healthcare
Charles River Laboratories International, Inc.73BAlignment Healthcare, Inc.71BAptarGroup, Inc.87ADENTSPLY SIRONA Inc.67BBruker Corporation77B+Acadia Healthcare Company, Inc.67BNeighbors
Middlesex →Key facts
CEOYvonne L. Greenstreet
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: ALNY
Employees2,500
IPO date2004-06-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.